Literature DB >> 16612335

Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).

C Licht1, S Heinen, M Józsi, I Löschmann, R E Saunders, S J Perkins, R Waldherr, C Skerka, M Kirschfink, B Hoppe, P F Zipfel.   

Abstract

We report a novel pathomechanism for membranoproliferative glomerulonephritis type II (MPGN II) caused by a mutant Factor H protein expressed in the plasma. Genetic analyses of two patients revealed deletion of a single Lys residue (K224) located within the complement regulatory region in domain 4 of Factor H. This deletion resulted in defective complement control: mutant protein purified from the plasma of patients showed severely reduced cofactor and decay-accelerating activity, as well as reduced binding to the central complement component C3b. However, cell-binding activity of the mutant protein was normal and comparable to wild-type Factor H. The patients are daughters of consanguineous parents. As both patients but also their healthy mother were positive for C3 nephritic factor, the mutant Factor H protein is considered relevant for unrestricted activation of the disease-causing activation of the alternative complement pathway. Replacement of functional Factor H by fresh frozen plasma (10-15 ml/kg/14 days) was well tolerated, prevented so far disease progression in both patients, and is in the long run expected to preserve kidney function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16612335     DOI: 10.1038/sj.ki.5000269

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  79 in total

1.  Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Authors:  Valérie Leroy; Véronique Fremeaux-Bacchi; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes; Marie-Alice Macher; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2010-12-25       Impact factor: 3.714

2.  The C-terminus of complement factor H is essential for host cell protection.

Authors:  Mihály Józsi; Martin Oppermann; John D Lambris; Peter F Zipfel
Journal:  Mol Immunol       Date:  2007-01-17       Impact factor: 4.407

Review 3.  Factor I and factor H deficiency in renal diseases: similar defects in the fluid phase have a different outcome at the surface of the glomerular basement membrane.

Authors:  Peter F Zipfel; Richard J H Smith; Christine Skerka
Journal:  Nephrol Dial Transplant       Date:  2008-12-04       Impact factor: 5.992

Review 4.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

5.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

6.  Circulating complement levels and C3 glomerulopathy.

Authors:  Fernando C Fervenza; Sanjeev Sethi
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-23       Impact factor: 8.237

Review 7.  Molecules Great and Small: The Complement System.

Authors:  Douglas R Mathern; Peter S Heeger
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-07       Impact factor: 8.237

8.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

Authors:  Sanjeev Sethi; Jeffrey D Gamez; Julie A Vrana; Jason D Theis; H Robert Bergen; Peter F Zipfel; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

Review 9.  Membranoproliferative glomerulonephritis.

Authors:  Bassam Alchi; David Jayne
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

10.  Structure of complement fragment C3b-factor H and implications for host protection by complement regulators.

Authors:  Jin Wu; You-Qiang Wu; Daniel Ricklin; Bert J C Janssen; John D Lambris; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.